Mobile App-based mHealth Interventions and Cardiovascular Risk Factors in Patients with Type 2 Diabetes: A Narrative Review.

BACKGROUND

Type 2 diabetes mellitus (T2DM) is associated with a high burden of cardiovascular disease (CVD), driven by clustering of poorly controlled risk factors. Despite clear evidence that multifactorial risk-factor control reduces CVD events, simultaneous achievement of guideline-recommended targets remains uncommon and challenging in clinical practice. Mobile app based mHealth have emerged as scalable tools to extend chronic disease management beyond traditional care settings.

OBJECTIVE

This is an updated narrative review on mobile app-based interventions in adults with type 2 diabetes mellitus, with a focus on their impact on major cardiovascular risk factors.

METHODS

We conducted a literature search on PubMed, Embase, Cochrane Library, Web of Science, and Scopus from inception to November 2025 for studies involving adults with T2DM, mHealth or smartphone app interventions, and cardiovascular risk factors.

RESULTS

mHealth interventions consistently produced modest but clinically relevant reductions in HbA1c (up to 0.8% in intensive, tailored programs) compared to usual care. Effects on systolic blood pressure were generally small and heterogeneous. Effects on lipid profile were limited and often non-significant; most benefits appeared mediated through improved statin initiation and adherence rather than direct lifestyle change. Weight, body mass index, and waist circumference revealed small improvement, primarily in lifestyle-focused apps with active diet and physical activity tracking. mHealth programs enhanced self-management behaviors and medication adherence. These studies are limited by substantial heterogeneity in populations, intervention components, comparators, outcome ascertainment, and by digital literacy and access barriers.

CONCLUSIONS

Mobile app-based interventions for T2DM reliably improve glycemic control and confer smaller, more variable benefits across other cardiovascular risk factors. Current evidence supports mHealth as an enabling component of comprehensive diabetes and cardiovascular risk management rather than a stand-alone therapy. Robust, longer-term trials in diverse, high-risk populations are needed to determine whether these digital strategies translate into durable reductions in major cardiovascular events.